SiegelRL,MillerKD,JemalA, 2015.,CA Cancer J Clin 65 5 -29
EganD,RadichJ, 2016.Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL,Best Pract Res Clin Haematol 29 252 -63
QinYZ,HuangXJ, 2016.Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia,Methods Mol Biol 1465 1 -15
DeiningerMW,O'BrienSG,GuilhotF, 2009.International randomized study of interferon vs STI571 (IRIS) 8-year followup: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract 1126],Blood 114 -
CaldemeyerL,DuganM,EdwardsJ,AkardL, 2016.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia,Curr Hematol Malig Rep 11 71 -9
HochhausA,O'BrienSG,GuilhotF, 2009.Six-year follow-up of patients receiving imatinib for the firstline treatment of chronic myeloid leukemia,Leukemia 23 1054 -61
7 Van HunselF,HärmarkL,PalS,OlssonS,van GrootheestK., 2012.Experiences with adverse drug reaction reporting by patients: an 11-country survey,Drug Saf 35 45 -60
TraskPC,CellaD,PowellC, 2013.Health related quality of life in chronic myeloid leukemia,Leuk Res 37 9 -13
FoodDrug, 2009.Administration: Guidance for Industry. Patientreported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, -
10 XiaoC,PolomanoR,BrunerDW, 2013.Comparison between patientreported and clinician-observed symptoms in oncology,Cancer Nurs 36 E1 -E16
JabbourE,SaglioG,RadichJ,KantarjianH, 2012.Adherence to BCRABL inhibitors: issues for CML therapy,Clin Lymphoma Myeloma Leuk 12 223 -29
MeriK,MarikkiP,MarjaA, 2015.Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment,Patient Prefer Adherence 9 1733 -40
USFood Drug, 2009.Administration: Guidance for Industry. Patientreported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, -
GanesanP,SagarTG,DubashiB, 2011.Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia,Am J Hematol 86 471 -4